Clinical Trial Update: Efficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial update for Xacrel (Ocrelizumab) in relapsing-remitting multiple sclerosis reports efficacy and safety data.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis
• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• Xacrel (ocrelizumab)

Snippet

Sponsor: Cinnagen | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED